Maze Therapeutics, Inc. (MAZE) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	20.0M	—	167.5M	—	—
Cost of Revenue	943.0K	2.4M	—	—	—
Gross Profit	19.1M	(2.4M)	167.5M	—	—
Operating Expenses
R&D Expense	121.4M	108.4M	83.5M	73.9M	88.2M
SG&A Expense	43.8M	34.5M	26.4M	24.6M	22.8M
General & Admin Expense	43.8M	34.5M	26.4M	24.6M	22.8M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(499.0K)	(2.4M)	—	—	—
Total Operating Expenses	164.7M	140.5M	109.9M	98.6M	111.0M
Cost and Expenses	165.6M	142.9M	109.9M	98.6M	111.0M
Operating Income (EBIT)	(145.6M)	(142.9M)	57.6M	(98.6M)	(111.0M)
Non-Operating
Interest Income	9.6M	11.8M	4.7M	2.0M	2.0M
Interest Expense	1.8M	—	—	—	—
Net Interest Income	7.8M	11.8M	4.7M	2.0M	2.0M
Other Non-Op Income/Expense	12.0M	11.8M	(4.2M)	(1.9M)	(3.9M)
Non-Operating Income (excl Interest)	(13.8M)	(11.8M)	4.2M	1.9M	3.9M
EBT (Pre-Tax Income)	(133.6M)	(131.1M)	53.4M	(100.4M)	(114.9M)
Income Tax Expense	—	—	1.2M	—	—
Bottom Line
Net Income	(133.6M)	(131.1M)	52.2M	(100.4M)	(114.9M)
Earnings from Cont. Ops	(133.6M)	(131.1M)	52.2M	(100.4M)	(114.9M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(133.6M)	(131.1M)	3.4M	(100.4M)	(114.9M)
Per Share
Basic EPS	($2.74)	($3.05)	$0.08	($2.29)	($2.63)
Diluted EPS	($2.74)	($3.05)	$0.08	($2.29)	($2.63)
Revenue Per Share	$0.34	$0.00	$3.82	$0.00	$0.00
Shares
Basic Shares Outstanding	59.0M	43.0M	43.8M	43.8M	43.8M
Diluted Shares Outstanding	59.0M	43.0M	43.8M	43.8M	43.8M
Profitability Metrics
EBITDA	(130.3M)	(128.7M)	56.7M	(96.3M)	(111.1M)
D&A	1.5M	2.4M	3.3M	4.1M	3.8M
EBIT	(131.8M)	(131.1M)	53.4M	(100.4M)	(114.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026